Stocks Health care AAPG
NASDAQ · Health careAscentage Pharma Group International (AAPG)
Ascentage Pharma Group International reported revenue of $134.3M in fiscal 2024. It posted a net loss of $55.5M. In fiscal 2024 capital spending exceeded operating cash flow by $18.6M. At December 31, 2024 it held $122.4M in cash against $228.6M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 29, 2026.
Key facts about Ascentage Pharma Group International
- Net worth
- Ascentage Pharma Group International has a market value (market cap) of $1.4B at the latest share price, and shareholders' equity of $36.2M on its balance sheet at December 31, 2024. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $134.3M, with a net loss of $55.5M.
- Cash flow
- In fiscal 2024 operations used $15.3M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on April 29, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Ascentage Pharma Group International does
Ascentage Pharma Group International is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AAPG.
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | $134.3M | -$55.5M | -$0.18 | -$18.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AAPG ranks in Health care
Latest SEC filings
What Ascentage Pharma Group International has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- October 28, 2026
- October 22, 2026
- October 21, 2026
- October 15, 2026
- September 29, 2026
- September 17, 2026
- August 20, 2026
- August 13, 2026
- August 5, 2026
Insider trades
What the people running Ascentage Pharma Group International did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 21, 2026 | Yang DajunChairman and CEO, Director | Exercised options | 95,575 | - |
| May 21, 2026 | Yang DajunChairman and CEO, Director | Exercised optionsindirect | 92,746 | - |
| May 21, 2026 | Zhai YifanChief Medical Officer | Exercised options | 92,746 | - |
| May 21, 2026 | Zhai YifanChief Medical Officer | Exercised optionsindirect | 95,575 | - |
Who owns AAPG
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
2 insiders reported holding 3,197,698 shares in total, about $49.6M at the last price.
| Holder | Shares |
|---|---|
| Yang DajunChairman and CEO, Director | 1,598,849405,280 held indirectly |
| Zhai YifanChief Medical Officer | 1,598,8491,193,569 held indirectly |
Questions about AAPG
What does Ascentage Pharma Group International do?
Ascentage Pharma Group International is a company in the Health care sector, listed on NASDAQ as AAPG. Its shares trade on NASDAQ under the ticker AAPG.
What is Ascentage Pharma Group International's net worth?
Ascentage Pharma Group International has a market value (market cap) of $1.4B at the latest share price, and shareholders' equity of $36.2M on its balance sheet at December 31, 2024. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ascentage Pharma Group International profitable?
No. In fiscal 2024 it reported a net loss of $55.5M on revenue of $134.3M.
How much revenue does Ascentage Pharma Group International make?
In fiscal 2024 Ascentage Pharma Group International reported revenue of $134.3M.
When did Ascentage Pharma Group International last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 29, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 5, 2026.
Similar companies
Compare AAPG with
Follow AAPG
Get an email when Ascentage Pharma Group International files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ascentage Pharma Group International tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.